Teva Pharmaceuticals USA Inc reported on Tuesday the receipt of approval from the Food and Drug Administration (FDA) for an autoinjector device for AJOVY (fremanezumab-vfrm) injection for treating migraine.
AJOVY is the only FDA-approved anti-CGRP that offers the flexibility of quarterly (675 mg) or monthly (225 mg) dosing options and the healthcare providers will be able to decide if an autoinjector is the right administration option for their needs.
In conjunction, the company's AJOVY autoinjector is expected to be available to patients in the coming months.
Teva Pharmaceuticals USA Inc is an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)( TASE:TEVA), which has been developing and producing medicines to improve people's lives for more than a century.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML